CYP2C19 genetic testing for Mavacamten and ischaemic stroke treatment: What does the result mean for cardiovascular prescribers in the UK and Europe?

Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):481-483. doi: 10.1093/ehjcvp/pvae040.

Authors

Emma F Magavern¹, John H McDermott^{2

3}, Mark J Caulfield¹, William G Newman^{2

3}

Affiliations

¹ William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London EC1M 6BQ, UK.
² Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester M13 9PL, UK.
³ Division of Evolution, Infection and Genomics, School of Biological Sciences, The University of Manchester, Manchester M13 9NT, UK.

PMID: 39175266
DOI: 10.1093/ehjcvp/pvae040

No abstract available

Publication types

Editorial

MeSH terms

Cytochrome P-450 CYP2C19* / genetics
Europe
Humans
Ischemic Stroke* / diagnosis
Ischemic Stroke* / genetics
Pharmacogenomic Testing
Pharmacogenomic Variants
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use
Predictive Value of Tests
United Kingdom / epidemiology

Substances

Cytochrome P-450 CYP2C19
CYP2C19 protein, human
Platelet Aggregation Inhibitors